Avista Capital Partners-backed Taconic Biosciences completed the acquisition of TransCure bioServices.

Avista Capital Partners-backed Taconic Biosciences, a biotechnology company specializing in genetically engineered mouse and rat models, completed the acquisition of TransCure bioServices, a provider of preclinical research services using humanized mouse models. Financial terms were not disclosed. "This acquisition establishes a fully integrated translational research engine giving researchers a more predictive, efficient, and reliable alternative than fragmented multi-vendor workflows," Mike Garrett, Taconic Biosciences CEO.